Article

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma

2024-12-20

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, able to thrive in a challenging tumor microenvironment. Current standard therapies, including surgery, radiation, chemotherapy, and chemoradiation, have shown a dismal survival prognosis, resulting in less than a year of life in the metastatic setting. The pressing need to find better therapeutic methods brought about the discovery of new targeted th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7451171a-9674-523b-a4eb-ddf0a58ace81
DOI: 10.20944/preprints202412.1753.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaDOI 10.20944/preprints202412.1753.v1Read

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Semantic proximity Read

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read

A Young Scientist's Guide to PDAC: Past, Present, and FutureSemantic proximity Read

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Semantic proximity Read

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.Semantic proximity Read

Molecular dissection of pancreatic cancer signaling: Toward targeted therapies for KRAS, MDM2-TP53, EGFR, and PI3K/AKT/mTOR.Semantic proximity Read